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Abstract
Background: Offering self-sampling to non-attendees of cervical screening increases screening attendance.
Methods: We used observations from two Finnish studies on the use of self-sampling among the non-attendees to
estimate in a hypothetical screening population of 100,000 women the possible costs per extra screened woman
and costs per extra detected and treated CIN2+ with three intervention strategies; 1) a primary invitation and a
reminder letter, 2) a primary invitation and a mailed self-sampling kit and 3) two invitation letters and a self-sampling
kit. The program costs were derived from actual performance and costs in the original studies and a national estimate
on management costs of HPV related diseases.
Results: The price per extra participant and price per detected and treated CIN2+ lesion was lower with a reminder letter
than by self-sampling as a first reminder. When self-sampling was used as a second reminder with a low sampler price
and a triage Pap-smear as a follow-up test for HPV-positive women instead of direct colposcopy referral, the eradication of
a CIN2+ lesion by self-sampling was not more expensive than in routine screening, and the addition of two reminders to
the invitation protocol did not increase the price of an treated CIN2+ lesion in the entire screened population.
Conclusions: As a first reminder, a reminder letter is most likely a better choice. As second reminder, the higher costs of
self-sampling might be compensated by the higher prevalence of CIN2+ in the originally non-attending population.
Keywords: Cervical cancer, Screening, Self-sampling, HPV-testing, Cost-evaluation
Background
A high coverage and participation rate throughout the
program is of primary importance to the success of a
screening program. The participation rate of the orga-
nized cervical cancer screening program in Finland is
currently at 70 % with a decreasing trend [1]. Non-
attenders contribute significantly to cervical cancer
incidence and mortality [2, 3].
Ways to improve the attendance rate include personal
invitations to screening, preferably with a pre-assigned
date and place for the screening appointment [4–6],
reminder letters or telephone reminders to non-
attendees [7–15], and, when appropriate, a GPs signa-
ture on the invitation [6, 16].
As a recent approach, offering self-sampling for HPV-
testing for the non-attendees of cervical screening might
increase screening attendance [13, 17–22]. In Finland,
offering self-sampling to non-attendees after primary in-
vitation (i.e. as a first reminder) increased total attend-
ance by 17 % and the yield of detected moderate or
more severe cervical intraepithelial lesions (CIN2+) by
13 % [12]. When self-sampling was offered as a second
reminder after two invitation letters (primary invitation
and a reminder letter), it increased total attendance
by 4 %, CIN2+ yield by 8 %, and yield of severe cervical
lesions or cancer (CIN3+) by 9 % [14]. However, the costs
to obtain these effects must also be considered before
making recommendations for routine practice.
Here we estimated differences in the program costs
of using self-sampling vs. using a reminder letter as a
first reminder for non-attendees after primary invita-
tions, and further, what could be the cost of using
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self-sampling as a second reminder after two invita-
tion letters.
Methods
In the Finnish cervical screening program, all women
aged 30–60 are invited to give a screening sample by
personal invitations in 5-year intervals. In addition, those
women belonging to a risk group based on the previous
abnormal screening results or anamnestic data are in-
vited within 1–2 years after the previous screening
round [23]. The responsibility to organize screening lies
within individual municipalities. Participation rate in the
organized program is currently less than70 % [1]. Exten-
sive opportunistic screening occurs beside the organized
program [24].
This cost analysis evaluation is based on two Finnish
studies on the use of self-sampling among non-attendees
of routine cervical screening, described in detail else-
where [12–14].
The first study was conducted in 2008–2009 as a part
of the routine screening program of the city of Espoo. It
evaluated the effects of using a self-sampling test as a
first reminder for non-attendees in a randomized setting
in comparison to a reminder letter. In 2009, approxi-
mately half of the reminder letter arm non-attendees
further received a self-sampling test as a second re-
minder [12].
The second study assessed the effect of using self-
sampling as a second reminder (i.e. among non-
attendees after a primary invitation and a reminder
letter) in a non-randomized setting in 31 Finnish muni-
cipalities in 2011–2012 [14].
Here we use the average participation rates, referral
rates and precursor lesion yields observed in the studies,
to estimate in a hypothetical population of 100,000
women invited to screening the costs per extra screened
woman and costs per extra detected and treated CIN2+
by three different invitation strategies: 1) a primary invi-
tation and a reminder letter, 2) a primary invitation and
a mailed self-sampling kit and 3) a primary invitation, a
reminder letter and a mailed self-sampling kit as a sec-
ond reminder (with two different follow-up strategies for
HPV-positive women). A flow chart of invitational strat-
egies is shown in Fig. 1.
The cost per extra screened woman was calculated by
including only the costs of the invitational system, pri-
mary screening test and, in the case of self-sampling,
possible triage testing. The cost per one detected and
treated CIN2+ case included all costs from the invita-
tional system and primary testing to colposcopic inves-
tigations, treatment and subsequent follow-up testing.
As no outcome information was available from the ori-
ginal studies, CIN2+ was used as a proxy for the po-
tential of increasing the impact of the program. The
cost per one extra eradicated CIN2+ case by each of
the reminders was compared to the cost of eradicating
a CIN2+ case in routine screening under the specula-
tion that if the price of an eradicated CIN2+ lesion in
routine screening is regarded acceptable and the price
per lesion does not increase after adding one to two
reminders to the protocol, the cost increase might be
acceptable.
The estimate was calculated assuming 70 % attend-
ance rate by primary invitation, use of Pap-smear as a
primary screening test and current national detection
rates of CIN lesions among screening participants as
baselines [1].
Participation rate with self-sampling as first reminder
was set at 32 % and as second reminder at 21 % [12, 14].
Participation with reminder letter was estimated at 27 %
as observed for reminder letters sent with pre-assigned
appointments [12, 14], but additional analysis was
performed to estimate the effect of open invitations
with lower participation rate of 14 % [14]. HPV-
positivity rate was set at 12 % as observed for Hybrid
Capture 2 (HC2; Qiagen, Gaithersburg, MD, USA) in
the studies.
Costs of screening
Only direct costs were considered in this analysis. The
cost estimates for Pap-smears, diagnostic colposcopies
and management of CIN2+ diseases were derived from a
previous evaluation on the costs of prevention and man-
agement of HPV-related diseases in Finland that used
mean national prices [25]. The costs were evaluated
from the health care provider perspective and were here
presented in 2012 prices.
The cost of a Pap-smear includes sample taking, ana-
lysis and registration. The cost of HPV-analysis was esti-
mated at 20 euros, but to accommodate for the
differences in cost with other analysis methods and
decreasing market prices, additional analysis was con-
ducted with cost estimates of 15 and 30 euros. The cost
of a CIN case includes diagnostic and treatment pro-
cedures and follow-up after treatment, and cost of a
CIN2+ case is here presented as the average of the
cost of a CIN2 and a CIN3 case. The cost of a case
referred to colposcopy that resulted in normal results
or minor cytological changes without CIN diagnosis
includes diagnostic procedures and follow-up.
The cost of a primary screening invitation includes the
costs of identifying the screening population from the
Population Register Centre and cost of the letter itself.
The cost of a reminder letter includes only the cost of
the letter itself. A common practice is to use an online
program for appointment scheduling and mailing the
invitations and identifying the non-attending population
in need of re-invitations.
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Cost estimates for self-sampling were estimated using
a price of 2.0 euros for the sampling device and the ac-
tual mean costs in the study of 2011–2012 for other re-
lated costs (other materials, logistics costs and mailing).
A higher price of 6.5 euros for the sampling device was
used in additional analysis.
Both original studies included an opt-out option for
the self-sampling offer. The opt-out rate was 15 % in
both studies. Calculations assuming 15 % opt-out rate
were made as an additional analysis.
Follow-up after an HPV-positive self-taken sample
In the evaluation of self-sampling as a first reminder, the
estimate was based on a Pap-smear triage follow-up with
82 % follow-up compliance rate [12]. In the original ran-
domized study of self-sampling vs. reminder letter as a
first reminder the CIN yields after respective interven-
tions differed somewhat between arms, but the numbers
were too small for reliable comparisons in the back-
ground cancer risk of the participants by respective
interventions or differences in clinical sensitivity by
Fig. 1 Evaluated invitational and follow-up strategies in a population of 100,000 women to be screened
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respective testing methods. Thus, in this analysis the
CIN detection rate is assumed to be similar in both in-
terventions. However, as there has been suggestions that
self-sampling might attract women with higher risk for
cancer [22, 26], additional analysis was conducted as-
suming 20 % and 50 % higher detection rates of CIN2+
by self-sampling than by reminder letter.
In the evaluations of using self-sampling as a second
reminder, estimates were calculated for two different
follow-up strategies for women with a hrHPV-positive
result in self-taken sample; for the strategy of inviting all
hrHPV-positive women for a triage Pap-smear, and for
the strategy of referring all of them directly for col-
poscopy and biopsies (Fig. 1). Compliance to follow-
up in Pap-smear triage was estimated to be 79 %
[12], but a lower rate of 70 % [14] was used in add-
itional analysis, and compliance to direct colposcopy
follow-up was set at 90 % [12, 14].
For the break-down of resource required for screening
a population of 100,000 women in the different invita-
tion strategies and a more precise rationale on the unit
numbers used in the estimate, see Table 1.
The original studies this analysis is based on were ap-
proved by the Ethical committee of the Hospital District
of Helsinki and Uusimaa (430/E9/07 HUS and 79/13/03/
03/2011) and National Institute for Health and Welfare
(THL/1465/6.02.00/2013). In the first randomized study
the participants gave their written consent for their sam-
ples to be used in the study [12, 13]. In the second study
no written consent was required for the use of the
screening-related data [14]. The data was anonymized
prior to analysis in both of the studies. In the current
analysis, no individual-level data was used and no extra
permissions for the use of data were required.
Results
Self-sampling vs. reminder letter as a first reminder
Considering only the costs of invitations and a primary
screening test, the cost per extra screened woman by a
reminder letter was 33 euros and by self-sampling 38–68
euros depending on the price of the sampler, HPV-
analysis and whether an opt-out strategy was used
(Table 2). Assuming similar CIN detection rates among
the participants of the respective interventions, the cost
of an extra detected and treated CIN2+ lesion was ap-
proximately 10,300 euros with a reminder letter, and
15,300–21,800 euros by self-sampling.
Self-sampling as a second reminder after two invitation
letters
The cost per extra screened woman (invitations and pri-
mary and triage testing only) by self-sampling as a sec-
ond reminder was 48–85 euros (Table 2). The price to
detect and eradicate a CIN2+ lesion by self-sampling
ranged from 12,100 to 27,700 euros. When self-sampling
was used as a second reminder with a sampler price of 2
euros and a Pap-smear triage, the cost of a CIN2+ lesion
detected by self-sampling (12,800 euros) was not higher
than one detected in routine screening after primary in-
vitation only (15,300 euros) or after two invitations
(14,400 euros). This applied also to higher HPV-analysis
cost of 30 euros (14,300 euros).
If a Pap-smear triage was used for women with a
HPV-positive result in the self-taken sample the addition
of two reminders to the invitation protocol did not in-
crease the price per treated CIN2+ lesion in the entire
screened population (15,300 euros with only primary in-
vitation vs. 14,200-14,900 euros after reminders). With
direct colposcopy referral for HPV-positive women the
cost per lesion in the entire population did increase
slightly (15,500–16,000 euros).
Discussion
In our model population of 100,000 women with original
participation rate at 70 %, total participation increased
to 78–79 % by one reminder and to 83 % by two re-
minders (reminder letter and consequent self-sampling)
and CIN2+ lesion yield increased by 21 % and 36-38 %,
respectively, when total costs increased by 14–29 % (one
reminder) and 26–44 % (two reminders).
As a first reminder, self-sampling was more expensive
than a reminder letter. Firstly, the cost per extra partici-
pating woman was higher (Table 2). Secondly, assuming
similar CIN2+ detection rates by self-sampling and re-
minder letters, or even a 20 % or 50 % higher detection
rate by self-sampling, the cost per treated CIN2+ lesion
by self-sampling was higher than with a reminder letter.
When self-sampling was used as a second reminder
with lower sampler price and a Pap smear triage, the
cost of a CIN2+ lesion detected by self-sampling was
not higher than one detected in routine screening. This
applied also to a higher cost of the HPV-analysis at 30
euros (Table 2). A lower follow-up compliance rate of
70 % compliance would increase the cost per detected
CIN2+ lesion, but with lower sampler price and lower
price of HPV-analysis it would still be lower than the
price per lesion with primary invitation only (14,000
versus 15,300 euros). Further, with Pap-smear triage,
adding self-sampling to the invitation protocol did not
increase the overall cost per treated CIN2+ lesion in
the study population as a whole—even with higher
sampler price, higher price of HPV-analysis or lower
(70 %) compliance to follow-up. This indicates more
lesions could be detected and treated with same cost
per lesion.
Strategies to improve participation have been consid-
ered cost-effective in improving the current cervical
cancer screening programs [27]. Further, as shown by a
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Table 1 Resource required for screening a population of 100,000 women in three different invitation strategies (costs included per strategy marked by ‘x’). Estimates on self-sampling
as a second reminder with two different follow-up strategies after a hrHPV-positive self-taken sample. For total costs per invitational strategy, see Table 2. Flow-chart on invitational






1 2 3a 3b Rationale for units needed Reference
x x x x Primary invitation 1.00 100,000 100,000
x x x x Pap-smear for attendees (70 %) 29.80 70,000 2,086,000 http://www.cancerregistry.fi/statistics, [25]
Diagnostic colposcopy 630 Average national rate of referrals for
diagnostic confirmations, 0.9 % of
attendees
http://www.cancerregistry.fi/statistics
x x x x No CIN diagnosisa 1,047.10 350 366,485 [25]
x x x x CIN1 case, inlc. treatment and follow-upb 1,863.40 70 130,438 Average national yield of
CIN1/CIN2+ lesions, 0.1 %/0.3 %
of attendees
http://www.cancerregistry.fi/statistics, [25]
x x x x CIN2+ case, inlc. treatment and follow-upb 2,512.00 210 527,520 http://www.cancerregistry.fi/statistics, [25]
First reminder: reminder letter
x x x Reminder letter 0.75 30,000 22,500
x x x Pap-smear for attendees (27 %) 29.80 8,100 241,380 [12, 14, 25]
Referral for diagnostic colposcopy 110 The pooled rate of referrals among
attendees by reminder letter in the
studies; 1.4 % (50/3,688)
[12, 14]
x x x No CIN diagnosisa 1,047.10 55 57,591 [25]
x x x CIN1 case, inlc. treatment and follow-upb 1,863.40 11 20,497 The pooled yields of CIN lesions
among participants after 1st reminder
in the studies; 0.1 % for CIN1 (6/4,444)
and 0.5 % for CIN2+ (24/4,444)
[12, 14, 25]
x x x CIN2+ case, inlc. treatment and follow-upb 2,512.00 44 110,528 [12, 14, 25]
First reminder: self-sampling
x Sampling devicec 2.00/6.50 30,000 60,000–195,000
x Information/invitation letter 0.75 30,000 22,500
x Outbound mailing and other logistic costsc 2.90 30,000 87,000
x Inbound mailing costs for attendees (32 %) 1.20 9,600 11,520 [12]
x HrHPV analysis for attendees (32 %) 20.00 9,600 192,000 [12]
x Response letter for attendees 0.75 9,600 7,200
Invitation for follow-up Pap-smear (hrHPV-positives) 1,152 12 % test positivity rate [12, 14]
x Follow-up Pap-smear 29.80 945 28,161 82 % compliance to follow-up [12, 14, 25]
Refererral for diagnostic colposcopy 210 The rate of colposcopies after
Pap-smear triage in the first study,
















Table 1 Resource required for screening a population of 100,000 women in three different invitation strategies (costs included per strategy marked by ‘x’). Estimates on self-sampling
as a second reminder with two different follow-up strategies after a hrHPV-positive self-taken sample. For total costs per invitational strategy, see Table 2. Flow-chart on invitational
strategies as Fig. 1 (Continued)
x No CIN diagnosisa 1,047.10 156 163,348 [25]
x CIN1 case, inlc. treatment and follow-upb 1,863.40 11 20,497 The yield of CIN lesions among
attendees after 1st reminder in the
studies (see above), but accounting
for 18 % loss in follow-up
[12, 14, 25]
x CIN2+ case, inlc. treatment and follow-upb 2,670.30 43 114,823 [12, 14, 25]
Second Reminder: self-sampling
x x Sampling devicec 2.00/6.50 21,900 43,800-142,350
x x Information/invitation letter 0.75 21,900 16,425
x x Outbound mailing and other logistic costsc 2.90 21,900 63,510
x x Inbound mailing costs for attendees (21 %) 1.20 4,599 5,519 [12, 14]
x x HrHPV analysis for attendees (21 %) 20.00 4,599 91,980 [12, 14]
x x Response letter for attendees 0.75 4,599 3,449
Follow-up: pap-smear triage
Invitation for follow-up Pap-smear (hrHPV-positives) 552 12 % test-positivity rate
x Follow-up Pap-smear 29.80 436 12,993 79 % compliance to follow-up [12, 14, 25]
x Referral for diagnostic colposcopy 83 Pooled rate of referrals after
Pap-smear triage in the studies,
19.1 % (9/47 Pap-smears taken)
[12, 14]
x No CIN diagnosisa 1,047.10 25 26,178 [25]
x CIN1 case, inlc. treatment and follow-upb 1,863.40 27 50,312 The pooled yield of CIN lesions
among test positive participants
compliant to follow-up in the
studies; 6.1 % for CIN1 (7/114) and
7.0 % for CIN2+ (8/114)
[12, 14, 25]
x CIN2+ case, inlc. treatment and follow-upb 2,670.30 31 82,779 [12, 14, 25]
Follow-up: direct colposcopy
Referral for direct colposcopy for hrHPV-positives 552 12 % test-positivity rate [14]
x No CIN diagnosisa 1,047.10 432 452,347 90 % compliance to follow-up
x CIN1 case, inlc. treatment and follow-upb 1,863.40 30 55,902 [12, 14, 25]
x CIN2+ case, inlc. treatment and follow-upb 2,670.30 35 93,461 [12, 14, 25]
a Includes also minor abnormalities without CIN diagnosis, average cost per case including diagnostic procedures and follow-up
b Average costs per CIN case, including diagnostic confirmation, possible treatment and follow-up















Table 2 Total resource required for screening and cost per detected and treated CIN2+ lesion (in euros). Estimates in self-sampling
as a 2nd reminder for two different follow-up strategies after a hrHPV-positive self-taken sample. In the main estimate, sampler price
is at 2.0 euros and cost of hrHPV-analysis at 20.0 euros. For breakdown of costs, see Table 1
Primary invitation
only




















Cost per screened woman (prim. testingb) 31 31 31 31 31
Total costs 3,210,443 3,210,443 3,210,443 3,210,443 3,210,443
Cost per treated CIN2+ 15,288 15,288 15,288 15,288 15,288
1st reminder
Cost per screened woman (prim. testingb) 43 33 33 33
Total costs 707,049 452,496 452,496 452,496
Cost per extra treated CIN2+ 16,443 10,284 10,284 10,284
2nd reminder
Cost per screened woman (prim. testingb) 53 50
Total costs 396,944 826,393
Cost per extra treated CIN2+ 12,805 23,611
Total costs of screening
Cost per screened woman (prim. testingb) 31 33 31 33 32
Total costs 3,210,443 3,917,492 3,662,939 4,059,883 4,489,332
Cost per treated CIN2+ 15,288 15,484 14,421 14,245 15,534
Total cost increase by reminders - 22 % 14 % 26 % 40 %
Achieved attendance rate 70.0 % 79.4 % 78.1 % 82.6 % 82.6 %
Increase in CIN2+ detection 20 % 21 % 36 % 38 %
Additional analysis:
Self-sampling opt-out rate 15 %
Cost per screened woman (prim. testingb) 41 49 47
Cost per detected CIN2+ (by reminder) 15,930 12,285 23,175
Sampler price = 6.5 euros
Cost per screened woman (prim. testingb) 58 75 72
Cost per CIN2+ lesion (by reminder) 19,583 15,984 26,427
Cost per CIN2+ lesion (total) 16,018 14,591 15,875
Cost of HPV-analysis = 15–30 euros
Cost per screened woman (prim. testingb) 38–54 48–63 45–60
Cost per CIN2+ lesion (by reminder) 15,327–18,676 12,063–14,288 22,954–24,925
Cost per CIN2+ lesion (total) 15,294–15,864 14,165–14,407 15,454–15,693
Sampler price = 6.5 euros & cost of
HPV-analysis = 30 euros
Cost per screened woman (prim. testingb) 68 85 82
Cost per CIN2+ lesion (by reminder) 21,815 17,467 27,741
Cost per CIN2+ lesion (total) 16,397 14,752 16,034
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recent modeling study, strategies that include offering
self-sampling to non-attendees generally are cost-
effective, unless hrHPV-testing on self-samples would be
substantially less accurate and regularly attending
women should switch to self-sampling, or the response
of non-attenders to use self-samplers would be poor
[28]. A recent Swedish randomized trial registered costs
of a self-sampling approach and by applying a ratio of
six treated CIN2+ lesions to avert one cancer, the au-
thors concluded this intervention would likely be cost-
saving and at least cost neutral [22]. In a Dutch study
the cost per extra CIN2+ lesion detected by self-
sampling among original non-attendees were in the
same range as those calculated for conventional cyto-
logical screening in the Netherlands [29]. In France,
Haguenoer et al. calculated incremental cost-
effectiveness ratios (ICERs) per extra screened non-
attending woman by self-sampling (63.2 euros) and by a
reminder letter (77.8 euros) compared to those screened
without extra interventions in France. The authors con-
cluded that the self-sampling strategy could be cost-
effective as compared with a reminder letter, as add-
itional costs of the self-sampling strategy were offset by
the substantial difference in participation [26]. Assuming
there would have been no screening attendance in the
reminded population without the interventions, the
costs per extra screened woman calculated in our study
(33 euros for reminder letter and 43 euros for self-
sampling, 38/54 if HPV-analysis price is set at 15/30
euros) are comparable to the ICERs calculated for the
French setting. The difference in attendance with the in-
terventions was so noticeable in the French study (23 vs.
10 %) that it compensated for the additional costs of the
self-sampling strategy. Based on our cost evaluation, this
was not the case in the Finnish setting.
In Finland, extensive opportunistic screening occurs
beside and independent of the organized program. The
overall 5-year coverage of any screening test has been
estimated at approximately 90 % among women in
screening ages [24]. Indeed, although offering self-
sampling to non-attendees has had a good impact on
screening attendance, its effect on overall test coverage
has been modest, as only 21–29 % of self-sampling par-
ticipants reported no Pap-smears within the last 5 years
and could thus be regarded under screened [12–14]. If the
cost per woman screened by self-sampling is calculated
Table 2 Total resource required for screening and cost per detected and treated CIN2+ lesion (in euros). Estimates in self-sampling
as a 2nd reminder for two different follow-up strategies after a hrHPV-positive self-taken sample. In the main estimate, sampler price
is at 2.0 euros and cost of hrHPV-analysis at 20.0 euros. For breakdown of costs, see Table 1 (Continued)
Compliance to Pap-smear triage = 70 %
Cost per CIN2+ lesion (by reminder) 18,553 13,966
Cost per CIN2+ lesion (total) 15,766 14,377
Compliance to Pap-smear triage = 70 % &
cost of HPV-analysis 30 euros & sampler
price = 6.5 euros
Cost per CIN2+ lesion (by reminder) 24,970 19,320
Cost per CIN2+ lesion (total) 16,705 14,892
CIN yield by self-sampling +20 %
compared to reminder letter (1.2 x yield
by reminder letter)
Cost per CIN2+ lesion (by reminder) 14,150
Cost per CIN2+ lesion (total) 15,066
CIN yield by self-sampling +50 %
compared to reminder letter (1.5 x yield
by reminder letter)
Cost per CIN2+ lesion (by reminder) 11,644
Cost per CIN2+ lesion (total) 14,421
Reminder letter participation rate = 14 %
Cost per CIN2+ lesion 10,693
Increase in costs by reminders 7.7 %
Increase in CIN2+ detection (total) 11.0 %
Assuming 70 % attendance rate with the primary invitation, 27/32 % attendance with first reminder (reminder letter/self-sampling, respectively), and 21 %
attendance rate with self-sampling as second reminder
a Follow-up for women with a HPV-positive result from the self-taken sample
b including only costs of invitations, primary screening test and possible triage testing
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only for the previously under screened self-sampling par-
ticipants, it rises up to 183–259 euros (sampler price 2–
6.5 euros).
On the other hand, total annual costs of all screening
tests in Finland have been estimated at 22.4 million
euros, of which 78 % comprised of opportunistic screen-
ing services with significant over screening among some
women and lower cost-effectiveness than that of the or-
ganized program [24, 25]. The price of an opportunistic
Pap-smear is clearly higher than one taken within the
organized program, 54–82 vs. 30 euros [24]. The price
of an opportunistic screening test is also higher than the
combined price of the invitational system and primary
testing per participant in the current estimate, even with
one or two reminders (31–34 euros). Thus minimizing
the number of opportunistic smears and increasing at-
tendance in organized screening by reminders and a
self-sampling option could decrease the overall costs of
screening. Importantly, the health benefits of screening
would hopefully be more evenly and equally distributed.
Self-sampling offers a different approach to screening, in
practical and emotional aspects, and can thus help to
tempt the current non-attendees of organized screening
to take part in the program [30].
We previously showed that reminder letters with
assigned appointments result in a two-fold attendance
rate (14 vs. 28 %) compared to open invitations that
require more of an initiative from the women [14]. How-
ever, if reminder letters are used by the Finnish munici-
palities, they are often open ones (no appointment).
When the participation rate of reminder letters was set
at a lower level of 14 %, the increase in cost reduced to
8 %, but the total participation rate would only rise up
to 74 % and increase in CIN2+ yield would naturally be
lower. However, the price per participant was still lower
than by self-sampling as a first reminder (Table 2). The
previous results and current estimate thus imply that as a
first reminder, reminder letters with pre-assigned appoint-
ment times and places are the most effective choice.
The follow-up strategy used for hrHPV-positive self-
sampling participants has a noticeable impact on the im-
mediate total costs of self-sampling, but it also might
have an impact on the rate of detected CIN2+ lesions, as
follow-up by direct colposcopy would most likely result
in higher compliance to follow-up. In these estimates
however, the assumed higher rate of CIN2+ detection in
the direct colposcopy approach did not even out the
higher costs in terms of cost per eradicated lesion. New
triage methods by molecular marker analysis of the self-
taken samples show promising results in directing the
right women to colposcopic examinations without the
extra screening visit a Pap-smear triage requires [31].
At lower sampler prices, the resulting savings of an
opt-out approach are limited. However, opt-out reduces
waste and is thus recommendable at all sampler prices.
An opt-in strategy where samplers are only mailed to
those who express an interest would most likely reduce
the costs of self-sampling. It does, however require more
of an initiative from the women who are already harder
to reach, and has generally resulted in lower attendance
rates, especially if contact letters offering self-sampling
are limited to only one or two [2, 21]).
Strengths and limitations
Both studies used for this cost analysis were embedded
in routine screening. The first study was conducted in a
setting where original attendance with primary invitation
was lower (63 %) and the second one in a setting with
higher (73 %) level of attendance than the national aver-
age of 70 %. They both achieved similar rates of partici-
pation by interventions in large and diverse populations
and resulting participation rates can thus be regarded re-
liable. Also a similar trend of higher CIN yield among
original non-attendees was seen in both studies. This
gives support to the generalizability of these findings.
In the original studies, the follow-up protocol was to
refer women with a hrHPV-positive self-taken sample
aged 40 years or older directly to a colposcopy and invite
women aged less than 40 years for a triage Pap-smear.
Due to the more complicated nature of the approach,
and the unlikelihood of it being used in routine practice,
this approach was not used here. Thus in the Pap-smear
triage the number of further referrals for colposcopies
(HPV-positive and abnormal cytology) was estimated
based on the colposcopy rate of women under 40 years
who were invited for triage Pap-smear in the studies,
although the referral rate might be age dependent in
reality.
Further, the cost used for colposcopic examinations
and follow-up for women with no CIN diagnosis was
quite high, 1,047 euros (vs. cost of colposcopy and biop-
sies alone, 300–500 euros). Women referred for colpos-
copy on the basis on HPV-positivity without cytological
changes (direct colposcopy after self-sampling) might
need less intensive follow-up than women referred due
to cytological abnormalities, and for them the used aver-
age cost might be an over estimation, but for compar-
ability the same cost was used for all colposcopy cases
without CIN diagnosis.
In the absence of information on longer term health
benefits achieved by the increase in attendance, such as
cancer reduction or life years gained, this evaluation fo-
cused on cost per treated CIN2+ lesion, which is clearly
an incomplete surrogate. As a further limitation, these
studies were planned to observe differences in attend-
ance rates, not in CIN yields. Thus, the resulting CIN
yields remained small, and are susceptible for chance,
depending for example upon diagnostic workup between
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laboratories. The estimated price per detected and
treated CIN2+ lesion should thus be interpreted with
caution.
A crucial aspect of HPV-testing on self-taken samples
is the heterogeneity between testing methods. A recent
meta-analysis concluded that when PCR-based HPV-
tests were used on self-taken samples the relative sensi-
tivity and specificity were similar to clinician-collected
samples. However, when less sensitive signal based as-
says such as HC2 were used, sensitivity of self-sampling
was lower, and often also specificity was lower. Both
studies used in this estimation used HC2 as the analysis
method, and referral rates, CIN yields and resulting
costs might vary for more sensitive methods [32]. The
clinical implications of the used follow-up strategy for
self-sampling HPV-positive women should be further in-
vestigated for more precise cost-efficacy analyses on this
aspect. Further, outcome evaluations, also with societal
perspectives (e.g. taking into account the patient’s time
costs in acquiring health care services), are needed for
final health economic analyses.
Conclusions
As a first reminder to non-attendees after primary invi-
tation, self-sampling might result in slightly higher at-
tendance rate, but the reminder letter with a pre-booked
screening appointment is still most likely a better choice
in terms of cost per extra screened woman and possibly
also cost per treated CIN2+ lesion.
When self-sampling was used as a second reminder
with lower sampler price and a triage Pap-smear instead
of direct colposcopy for HPV-positive women, the eradi-
cation of an extra CIN2+ lesion by self-sampling was
not more expensive than in routine screening. Based on
this surrogate information it thus seems that the higher
prevalence of precursors in the non-attending popula-
tion might even out the higher costs of self-sampling in
terms of price per treated precursor lesion. The imple-
mentation of self-sampling as a second reminder to
non-attendees is worth exploring further.
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